KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Other Operating Expenses for 11 consecutive years, with $211.1 million as the latest value for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 197.18% year-over-year to $211.1 million; the TTM value through Mar 2026 reached $822.0 million, up 150.26%, while the annual FY2025 figure was $681.9 million, 110.86% up from the prior year.
  • Other Operating Expenses hit $211.1 million in Q1 2026 for Alnylam Pharmaceuticals, down from $267.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $267.7 million in Q4 2025 and bottomed at $35.6 million in Q1 2022.
  • Average Other Operating Expenses over 5 years is $99.7 million, with a median of $84.3 million recorded in 2023.
  • Year-over-year, Other Operating Expenses decreased 19.56% in 2024 and then soared 197.18% in 2026.
  • Alnylam Pharmaceuticals' Other Operating Expenses stood at $51.3 million in 2022, then soared by 67.48% to $85.9 million in 2023, then grew by 19.75% to $102.8 million in 2024, then skyrocketed by 160.39% to $267.7 million in 2025, then fell by 21.14% to $211.1 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $211.1 million, $267.7 million, and $200.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.